Pharma Deal Frenzy May Continue in 2016, Jefferies Survey Finds

  • 77% of those surveyed see M&A activity levels steady or rising
  • About 20 percent see overpaying as risk as premiums stay high

The record year for pharmaceutical and biotech deals may spill over into 2016, according to a survey by Jefferies Group LLC.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.